1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Ilyang Pharmaceutical Co.,Ltd

Ilyang Pharmaceutical Co.,Ltd

007570.KS
Ilyang Pharmaceutical Co.,LtdKR flagKorea Exchange
8,410.00
KRW
+90.00
- -
150.75BMarket Cap

Total Valuation

Ilyang Pharmaceutical Co.,Ltd carries a market capitalization of 149.67B, placing it among publicly traded companies globally. Its enterprise value stands at 278.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap149.67B
Enterprise Value278.53B

Share Statistics

Ilyang Pharmaceutical Co.,Ltd currently has 17.92M shares outstanding.

Shares Outstanding17.92M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Ilyang Pharmaceutical Co.,Ltd trades at a trailing price-to-earnings ratio of 9.96. The price-to-sales ratio is 0.73, and the price-to-book ratio stands at 1.10.

PE Ratio9.96
PS Ratio0.73
PB Ratio1.10
P/TBV Ratio0.87
P/FCF Ratio3.67
P/OCF Ratio4.62

Enterprise Valuation

On an enterprise value basis, Ilyang Pharmaceutical Co.,Ltd trades at an EV/EBITDA multiple of 14.05 and an EV/FCF ratio of 4.99. The EV/Sales ratio of 1.01 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 14.05 provides insight into valuation relative to core operating earnings.

EV / Sales1.01
EV / EBITDA14.05
EV / EBIT14.05
EV / FCF4.99

Financial Position

Ilyang Pharmaceutical Co.,Ltd maintains a current ratio of 0.93, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.74, indicating elevated leverage, while an interest coverage ratio of 13.68 demonstrates strong ability to service its debt obligations.

Current Ratio0.93
Quick Ratio0.24
Debt / Equity43.74
Debt / EBITDA5.68
Interest Coverage13.68

Financial Efficiency

Ilyang Pharmaceutical Co.,Ltd posts a return on equity of 13.81 and a return on invested capital of 4.04.

Return on Equity (ROE)13.81
Return on Assets (ROA)4.47
Return on Invested Capital (ROIC)4.04
Return on Capital Employed (ROCE)7.97
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.57

Taxes

Over the trailing twelve months, Ilyang Pharmaceutical Co.,Ltd has paid 7.52B in income taxes, reflecting an effective tax rate of 27.00.

Income Tax7.52B
Effective Tax Rate27.00

Stock Price Statistics

Ilyang Pharmaceutical Co.,Ltd's stock has declined approximately -36.74242% over the past 52 weeks. The 50-day moving average sits at 11,047.40, while the 200-day moving average is 12,521.40.

Beta (5Y)N/A
52-Week Price Change-36.74242%
50-Day Moving Average11,047.40
200-Day Moving Average12,521.40
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Ilyang Pharmaceutical Co.,Ltd generated 275.51B in revenue and converted that into 20.16B in net income, yielding earnings per share of 1,133.98. EBITDA reached 19.83B, while operating income came in at 19.83B.

Revenue275.51B
Gross Profit112.29B
Operating Income19.83B
Pretax Income27.83B
Net Income20.16B
EBITDA19.83B
EBIT19.83B
Earnings Per Share (EPS)1,133.98

Balance Sheet

Ilyang Pharmaceutical Co.,Ltd holds 39.66B in cash and equivalents against 112.65B in total debt, resulting in a net debt position of 77.18B. Total book value stands at 182.51B, with working capital of -10.91B providing operational flexibility.

Cash & Cash Equivalents39.66B
Total Debt112.65B
Net Debt77.18B
Equity (Book Value)182.51B
Book Value Per Share10,185.91
Working Capital-10.91B

Cash Flow

Ilyang Pharmaceutical Co.,Ltd produced 43.51B in operating cash flow over the past twelve months. After subtracting -11.20B in capital expenditures, free cash flow totaled 32.31B - equivalent to 1,803.37 per share.

Operating Cash Flow43.51B
Capital Expenditures-11.20B
Free Cash Flow32.31B
FCF Per Share1,803.37

Margins

Ilyang Pharmaceutical Co.,Ltd operates with a gross margin of 40.76, reflecting its pricing power and cost economics. The operating margin of 7.20 and net profit margin of 7.32 provide insight into operational efficiency.

Gross Margin40.76
Operating Margin7.20
Pretax Margin10.10
Profit Margin7.32
EBITDA Margin7.20

Dividends & Yields

The company's payout ratio of 15.55 indicates the proportion of earnings distributed to shareholders.

Dividend Per Share177.64
Dividend YieldN/A
Payout Ratio15.55
Shareholder Yield3.16
FCF Yield27.24

Stock Splits

Ilyang Pharmaceutical Co.,Ltd's most recent stock split took place on March 4, 2011 with a 125:131 split ratio.

Last Split Date3/4/2011
Split Ratio125:131

Scores

Ilyang Pharmaceutical Co.,Ltd posts an Altman Z-Score of 1.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.76